Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGE-102
- Development stage
- Phase 2
- Lead developer
- BioAge Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BGE-102 is an orally available, small-molecule inhibitor of NLRP3 (NACHT, LRR and PYD domains-containing protein 3), developed by BioAge Labs. It is designed to penetrate the brain and inhibit NLRP3 inflammasome activity, a key driver of neuroinflammation. The drug has potential best-in-class features including high potency and high brain penetration, making it suitable for treating neuroinflammatory conditions such as those linked to metabolic diseases like obesity. As of early 2025, BGE-102 remains in preclinical development with IND-enabling studies underway; Phase 1 single ascending dose (SAD) data are anticipated by the end of 2025.
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on BGE-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGE-102.